340B 'Penny Pricing' Policy Draws Manufacturers' Ire
This article was originally published in The Pink Sheet Daily
Manufacturers pinpoint flaws in and outline alternatives to HRSA's plan to codify the now non-binding policy of charging a penny per pill for certain products. Concerns are raised about stockpiling and drug diversion, in addition to fair payment.
Register for our free email digests: